Moingeon Philippe, Floch Véronique Bordas-Le, Airouche Sabi, Baron-Bodo Véronique, Nony Emmanuel, Mascarell Laurent
Stallergenes Greer, Research Department, 6 rue Alexis de Tocqueville, 92183 Antony Cedex, France.
Immunotherapy. 2016 May;8(5):555-67. doi: 10.2217/imt-2015-0027.
As of today, allergen immunotherapy is performed with aqueous natural allergen extracts. Recombinant allergen vaccines are not yet commercially available, although they could provide patients with well-defined and highly consistent drug substances. As Bet v 1 is the major allergen involved in birch pollen allergy, with more than 95% of patients sensitized to this allergen, pharmaceutical-grade recombinant Bet v 1-based vaccines were produced and clinically tested. Herein, we compare the clinical results and modes of action of treatments based on either a birch pollen extract or recombinant Bet v 1 expressed as hypoallergenic or natural-like molecules. We also discuss the future of allergen immunotherapy with improved drugs intended for birch pollen-allergic patients suffering from rhinoconjunctivitis.
截至目前，变应原免疫疗法是使用水性天然变应原提取物进行的。重组变应原疫苗尚未上市，尽管它们可以为患者提供明确且高度一致的药物。由于Bet v 1是桦树花粉过敏中涉及的主要变应原，超过95%的患者对该变应原致敏，因此生产了药用级基于重组Bet v 1的疫苗并进行了临床试验。在此，我们比较了基于桦树花粉提取物或表达为低变应原性或天然样分子的重组Bet v 1的治疗方法的临床结果和作用模式。我们还讨论了用于患有 rhinoconjunctivitis 的桦树花粉过敏患者的改良药物的变应原免疫疗法的未来。
